Salirasib (Concordia Pharmaceuticals) is an oral rat sarcoma (RAS) inhibitor that causes dislocation of RAS by competing directly with farnesylated RAS in binding to its membrane-anchoring proteins. A phase I study was conducted to evaluate the safety and efficacy of Salirasib in patients with advanced leukemia. No dose-limiting toxicity was observed, and Grade 1/2 diarrhea was the only frequent nonhematologic toxicity seen. The safety profile of Salirasib and its relevant target makes it ideal to be used in combination therapy. Background: Rat sarcoma (RAS)/rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase activation (mutational or nonmutational) is a key pathway for survival and proliferative advantage of leukemic cells. Salirasib (Concordia Pharmaceuticals) is an oral RAS inhibitor that causes dislocation of RAS by competing directly with farnesylated RAS in binding to its putative membrane-binding proteins. Salirasib does not inhibit farnesyl transferase enzyme. Patients and Methods: We report on a phase I study of Salirasib in patients with relapsed/refractory hematologic malignancies. Salirasib was administered orally twice daily on days 1 to 21 of a 28-day cycle in a "3þ3" dose escalation design. Results: Seventeen patients with relapsed/refractory leukemia were treated for a median of 4 cycles (range, 1-29). Three patients each were enrolled at a dose level of 100, 200, 400, 600, and 800 mg twice daily and 2 patients at a dose level of 900 mg twice daily. No dose-limiting toxicities were encountered. Grade 1/2 diarrhea was the only frequent nonhematologic toxicity observed in 14 of 17 (82%) patients and was resolved with oral antidiarrheal agents. Eight (47%) patients (4 with myelodysplastic syndrome, 2 with acute myeloid leukemia, 1 with chronic myelomonocytic leukemia, and 1 with chronic myeloid leukemia) had hematological improvement; 1 in 3 lineages, 1 in 2 lineages, and 6 in 1 lineage. None of the patients achieved complete remission. The responses lasted for a median of 10 weeks (range, 5-115). The study was discontinued because of financial constraints. Conclusion: Salirasib was well tolerated and showed modest activity in relapsed/refractory hematological malignancies. The safety profile of Salirasib and its hematological malignancy relevant target makes it a potential drug to be used in combination therapy.
Introduction
Human cancers frequently express activating mutations in the oncogenic rat sarcoma (RAS). The frequency of mutated RAS genes and the type of mutated RAS gene (H-RAS, K-RAS, or N-RAS) varies widely depending on the tumor type. Mutated K-RAS, the most frequently mutated gene in cancer; is detected in high frequencies in pancreatic (90%) and colorectal carcinomas (50%), and is less frequent in hematological malignancies, where N-RAS mutations are relatively more frequent. [1] [2] [3] RAS proteins transduce growth and differentiation signals from receptor tyrosine kinases to the cell nucleus, thereby initiating gene transcription. 4 Mutated can also be mediated alternatively by constitutive activation of tyrosine kinase-like FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) or mutations in RAS-regulating gene mutations. [6] [7] [8] [9] By blocking the mutated RAS gene product, such malignant transformation can be reversed. 10 Several studies have reported the incidence and prognostic effect of the RAS mutation in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients. The acquisition of a RAS mutation in MDS has been shown to be associated with increased frequency of transformation to AML and shortened survival. 11, 12 Takahashi et al in a retrospective review reported that a subset of patients with low-/intermediate-risk MDS who acquire the RAS mutation in their disease course had shorter transformation-free survival to AML and overall survival in contrast to wild type patients. 13 In view of the importance of the oncogenic RAS in human cancer, and evidence of oncogenic RAS playing a major role in tumor proliferation and maintenance, targeting RAS proteins have become one of the novel therapeutic approaches.
14 Direct targeting of RAS has been difficult but RAS transforming activity can potentially be inhibited using different approaches. One is the inhibition of farnesylation of RAS, as exemplified by the farnesyl transferase inhibitors (FTIs). 15 Several FTIs have reached the clinic, including tipifarnib, lonafarnib, and BMS-214662. [16] [17] [18] [19] However, FTIs are not effective RAS inhibitors; they do not block the oncogenic activity of the 2 most frequently occurring oncoproteins K-RAS and N-RAS, because these 2 isoforms undergo alternative lipid modification by prenylation. 20, 21 Thus, the potential effectiveness of FTIs is limited by the existence of an alternative escape pathway permitting prenylation when RAS farnesylation is blocked by FTIs.
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Marom et al 24 at Tel Aviv University applied rational drug design to target RAS by competitively inhibiting the enzyme prenylated protein methyltransferase (PPMTase), which methylates the carboxyl-terminal S-prenylcysteine in a large number of prenylated proteins including RAS. Salirasib (trans-farnesylthiosalicylic acid (FTS); Concordia Pharmaceuticals) is a synthetic S-prenyl derivative of thiosalicylic acid, resembling the carboxyl-terminal farnesylcysteine common to all RAS proteins. In a cell-free system, FTS inhibits RAS methylation, but not farnesylation. In intact cells PPMTase inhibition is unlikely to be the mechanism of inhibition for RAS-mediated growth by FTS, because significantly high concentrations are needed in intact cells to inhibit methylation. In cellular systems, Salirasib reduces RAS in cell membranes by dislodging RAS from membrane anchoring sites, and inhibits the growth of all types of RAS-driven cancer. 25, 26 Preclinical data showed that exposure to Salirasib using oral gavage results in tumor growth inhibition and prolonged survival in xenotranplants of a variety of human tumors in mice. In vitro and ex vivo studies have shown that Salirasib dislodges the active RAS protein from the cell membrane, thereby blocking the initiation of downstream signaling events, inhibiting tumor cell proliferation, and promoting cancer cell apoptosis. 24, [27] [28] [29] This work has been translated in few clinical trials for patients with solid tumors.
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Here, we present our result from a phase I trial, exploring role of oral Salirasib in patients with advanced hematological malignancies.
The primary objective of this study was to determine the maximum tolerated dose (MTD), pharmacokinetics (PK), and dose-limiting toxicities (DLT). Secondary objectives were to evaluate response in patients with advanced hematological malignancies.
Patients and Methods

Patient Population
Patients were eligible if they had relapsed/refractory hematologic malignancies for which no standard therapies were anticipated to result in a durable response or who refused or were considered unsuitable for standard therapy. Other eligibility criteria included age ! 18 years, and Eastern Cooperative Oncology Group performance status of 0 to 2. In the absence of rapidly progressing disease, the washout from previous treatment to time of study drug administration had to be at least 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents. Patients needed to have adequate organ function indicated by serum creatinine 2.0 mg/dL; total bilirubin 2.0 mg/dL; alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) no more than 3 times the upper limit of normal range unless the abnormal parameter level was considered related to leukemia. The study protocol was approved by the institutional review board and all patients were required to provide written informed consent. The trial was registered with www. clinicaltrials.gov (NCT00867230).
Study Design
The study design was a 3þ3 design with 6 planned dose levels and accelerated dose escalation. The first 2 escalations were at 100%, the next 3 were at 50%, 33%, and 12%, respectively. Escalation to the next dose level was done only after the third patient at the previous dose level had been observed for 4 weeks and no DLT was observed.
The National Cancer Institute Common Toxicity Criteria version 3.0 was used to grade toxicity. DLT were defined as clinically significant toxicity or abnormal laboratory value assessed as being unrelated to disease progression, coexisting illness, or concomitant medications, and occurring during the first cycle. This included Grade 3 AST/ALT increased levels for 7 days, any Grade 4 AST/ALT level increase, and other clinically significant nonhematological adverse events Grade ! 3. Clinically not significant events like nausea and vomiting Grade 3, alopecia, study drugrelated fever, electrolyte abnormalities (including K, Na, CL, HCO 3 , Mg, Ca, and bilirubin) Grade 3 were excluded from definition of the DLT.
Response Criteria
A complete remission (CR) was defined as disappearance of all clinical evidence of disease with < 5% bone marrow blasts, neutrophil count ! 1.0 Â 10 9 /L, and platelet count ! 100 Â 10 9 /L. Partial response (PR) required all of the hematologic values for a CR but with a decrease of ! 50% in the percentage of blasts to 5% to 25% in the bone marrow aspirate. Hematologic improvement was defined as reported by Cheson et al. 32 Briefly, in patients with pretreatment hemoglobin levels < 11 g/dL, erythroid responses required an increase of at least 1.5 g/dL. Platelet responses were evaluated in patients with pretreatment platelet levels 
Statistical Methods
The primary outcome measure in the study was the safety of escalating doses of FTS. The sample size was not determined with statistical power consideration. Descriptive statistics on patient characteristics, analysis of toxicities, and outcome were performed on all patients.
Pharmacokinetic Assessments
Plasma levels of FTS were determined at specified time points using a high performance liquid chromatography method, with a limit of quantitation at 1 ng/mL. Blood samples for PK analysis were collected during cycle 1 on treatment days 1, 8, and 15 at multiple time points. The following pharmacokinetic parameters were calculated: maximum plasma concentration (C max ), the time to C max , terminal half-life (T 1/2 ), area under the concentration time curve, to infinity, and systemic clearance.
Results
Patient Characteristics
Seventeen patients were enrolled in the study and all of them were evaluable for response and toxicity. Patient demographic and disease characteristics are listed in Table 1 . Eleven (65%) were male. The median age was 72 years (range, 35-85). Eight (50%) patients had AML, 5 (28%) had MDS, 2 (12%) had chronic myelomonocytic leukemia (CMML), and 1 patient each with myelofibrosis, and chronic myeloid leukemia (CML). Seven patients (41%) had diploid cytogenetics (CG), 5 had (29%) -5/-7, and 2 (12%) had complex CG. The median number of previous therapies was 2 (range, 0-7). One patient received Salirasib as firstline therapy because the treating physician believed that the patient was not a candidate for intensive anthracycline or cytarabine-based therapy because of advance age, comorbidities, and poor performance status. Three (18%) patients received Salirasib as a first-line therapy. Thirteen (76%) patients were evaluated for RAS mutations and only 1 patient had a RAS mutation (N-RAS). Among the other mutations tested was FLT3 ITD in 14 (82%) patients and all were wild type.
Dose Levels and Toxicity
Salirasib was administered orally twice daily on days 1 to 21 in a 28-day cycle. The starting dose level was 100 mg. Three patients were treated at each dose level from 1 to 5 (100, 200, 400, 600, and 800 mg) and 2 patients at the sixth dose level (900 mg; Table 2 ). Cycle 1 was the DLT defining period. All 17 patients were evaluable for toxicity. No dose-limiting toxicity was observed. Nonhematological toxicities are shown in Table 3 . The most common toxicity was diarrhea (Grade 1 and 2), experienced by 11 (65%) of patients. None of the patients with diarrhea required dose interruptions. Other nonhematological toxicities (all grades) included increase in transaminase levels 8 (47%), hyperbilirubinemia 2 (12%), and increase in creatinine 2 (12%). Only 1 patient had Grade 4 hyperbilirubinemia, who had pre-existing Grade 3 hyperbilirubinemia secondary to leukemia (Table 3) .
No DLT were encountered in patients who continued therapy beyond cycle 1. Further dose escalations were stopped because of logistical reasons, primarily involving a financial decision made by the sponsor.
Efficacy
Eight of 17 (47%) patients achieved responses. None of the patients achieved CR, CR with incomplete platelet recovery (CRp), or PR. All responders had hematological improvements: 1 with trilineage response, 1 with bilineage response, and 6 (23.5%) with 1 lineage response. Among patients with 1 lineage response; 3 had improvement in platelet count, 2 had improvement in absolute neutrophil count (ANC), and 1 had improvement in hemoglobin. The patient with trilineage hematopoietic response had MDS with complex CG (including monosomy 7) and received Salirasib as second-line therapy. The patient with bilineage response had MDS with marrow fibrosis, and achieved improvement in hemoglobin and platelet count. Three patients with improvement in platelet count alone had relapsed refractory AML (n ¼ 1), CMML (n ¼ 1), and high risk MDS (n ¼ 1). Two patients with improvement in ANC had multiply relapsed refractory AML, and one of them had complex CG. Another patient with improvement in hemoglobin had CML with refractory disease and 6 lines of therapy failed. Only 1 patient in the study had a RAS mutation; however he was not among responders. Responses were observed at more than 1 dose level. Two (12%) patients had a response at the 200-mg twice daily dose, 2 (12%) at the 400-mg dose, 2 (12%) at the 600-mg dose, and 1 patient each had a response at the 800-mg and 900-mg twice daily dose level. The median time to response was 30 days (range, 9-116 days). The median response duration was 10 weeks (range, 5-115 weeks) and median number of cycles that patients received was 4 (range, 1-29). Reponses are summarized in Table 4 . 
Pharmacokinetics
Discussion
This is the first report of a prospective clinical trial of Salirasib in patients with hematological malignancies. Our study showed that oral Salirasib was well tolerated at all tested dose levels and DLT were not observed. The only significant toxicity was diarrhea (Grade 1-2). None of the patients had Grade 3 or 4 toxicity apart from 1 patient with Grade 4 hyperbilirubinemia, who had baseline Grade 3 hyperbilirubinemia due to advanced leukemia. In this study, 8 of 17 (47%) of the patients achieved protocoldefined responses. Although all responses were in improvement in cytopenias only, no dose-response relationship was seen. In fact, 4 (57%) responders received low-dose levels of 200 mg and 400 mg twice daily. The study did not formally determine a MTD; further dose escalations were stopped because of logistical reasons. Correlative studies of target inhibition were unfortunately not included in this trial to answer response relationship with target modulation.
Only 1 patient enrolled in our study was found to have a RAS mutation (N-RAS), however, this patient was not among the responders. In this study, all of the responders had unmutated RAS, an observation consistent with several previously published results demonstrating lack of correlation between RAS mutational status and response to RAS-targeting therapy. 33, 34 In contrast, in a more recent trial of trametinib, targeting mitogenactivated protein kinase (MEK) 1 and 2 downstream of RAS in myeloid malignancies, most responses including in those with CR were seen in patients with mutations in the RAS gene. 35 Among the 87 patients enrolled in the clinical trial, 57 (65%) of patients had N-RAS/K-RAS mutation. Among the patients with mutated N-RAS/K-RAS the CR/CRp/marrow CR rate was 21% compared with 3% in patients with wild type N-RAS/K-RAS. Trametinib is active in sequential or combination therapy with BRAF (v-raf murine sarcoma viral oncogene homolog B1) inhibitors in patients with BRAF-mutant melanoma, confirming its oncogenic pathway-dependent role.
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Conclusion
Oral Salirasib was well tolerated with modest activity in relapsed and refractory hematological malignancies. Because of its very limited toxicity profile with oral dosing and relevance of its target in hematological malignancies, Salirasib can potentially be used in combination strategies including those with hypomethylating agents or kinase (FLT3, KIT [tyrosine-protein kinase Kit], MEK) inhibitor-targeted therapies.
Clinical Practice Points
Mutated RAS (K-RAS, N-RAS, or H-RAS), is the most frequently mutated gene in human cancer. RAS proteins transduce growth and differentiation signals from receptor tyrosine kinases to the cell nucleus, thereby initiating gene transcription and leading to tumor growth. By blocking the mutated RAS gene product, such malignant transformation can be reversed. The dynamic acquisition of RAS mutations in MDS have been shown to be associated with increased frequency of transformation to AML and shortened survival. In view of the importance of oncogenic RAS and evidence of it playing a major role in tumor proliferation and maintenance, targeting RAS proteins have become one of the novel therapeutic approaches. Salirasib is an oral RAS inhibitor; it reduces RAS in cell membranes by dislodging from its membrane binding sites, and inhibits the growth of all types of RAS-driven cancer. Salirasib is not an FTI. In our phase I study, Salirasib was well tolerated in a relapsed/ refractory leukemia population. No DLT were observed, and Grade 1/2 diarrhea was the only most frequent nonhematological toxicity observed. Although modest, Salirasib has shown efficacy in heavily treated, advanced leukemia patients. Eight (47%) patients achieved hematological improvement with durable responses, lasting for a median of 10 (range, 5-115) weeks. Salirasib demonstrated a good safety profile and relevance of its target in hematological malignancies warrants future combination studies with chemotherapy or targeted agents.
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